Sanofi Past Earnings Performance

Past criteria checks 5/6

Sanofi has been growing earnings at an average annual rate of 13.1%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 5.5% per year. Sanofi's return on equity is 12.6%, and it has net margins of 19.8%.

Key information

13.1%

Earnings growth rate

13.0%

EPS growth rate

Pharmaceuticals Industry Growth	12.4%
Revenue growth rate	5.5%
Return on equity	12.6%
Net Margin	19.8%
Next Earnings Update	01 Feb 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sanofi makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BMV:SAN1 N Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 23	45,699	9,066	10,703	6,679
30 Jun 23	46,045	8,617	10,783	6,752
31 Mar 23	46,199	8,357	10,767	6,780
31 Dec 22	45,389	8,371	10,539	6,706
30 Sep 22	44,348	6,409	10,399	6,468
30 Jun 22	42,039	6,643	10,025	6,176
31 Mar 22	40,342	6,666	9,784	5,914
31 Dec 21	39,175	6,223	9,599	5,692
30 Sep 21	38,496	6,174	9,457	5,622
30 Jun 21	37,546	5,777	9,362	5,501
31 Mar 21	36,939	12,197	9,301	5,455
31 Dec 20	37,369	12,294	9,448	5,530
30 Sep 20	37,650	11,224	9,613	5,699
30 Jun 20	37,692	11,138	9,729	5,738
31 Mar 20	38,234	3,453	9,936	5,973
31 Dec 19	37,631	2,855	9,967	6,020
30 Sep 19	36,940	3,179	9,951	6,010
30 Jun 19	36,763	3,591	9,959	6,111
31 Mar 19	36,264	4,439	9,998	5,999
31 Dec 18	35,677	4,319	9,934	5,894
30 Sep 18	35,316	4,041	9,906	5,680
30 Jun 18	34,985	3,243	9,918	5,560
31 Mar 18	35,428	3,539	9,980	5,443
31 Dec 17	36,221	3,773	10,164	5,472
30 Sep 17	36,400	4,593	10,077	5,445
30 Jun 17	36,315	4,744	10,034	5,325
31 Mar 17	35,677	4,682	9,866	5,246
31 Dec 16	34,696	4,395	9,592	5,172
30 Sep 16	34,349	4,195	9,479	5,099
30 Jun 16	34,115	4,154	9,452	5,191
31 Mar 16	34,569	4,440	9,458	5,158
31 Dec 15	34,861	4,411	9,496	5,082
30 Sep 15	37,201	5,292	10,154	5,195
30 Jun 15	32,910	4,628	8,873	4,745
31 Mar 15	35,074	4,329	9,609	4,884
31 Dec 14	31,999	4,273	8,565	4,667
30 Sep 14	33,484	4,112	8,945	4,719
30 Jun 14	33,134	4,140	8,640	4,755
31 Mar 14	33,074	3,812	8,699	4,752
31 Dec 13	31,291	3,639	8,107	4,605
30 Sep 13	33,424	3,127	8,824	4,895
30 Jun 13	34,146	3,364	9,153	4,840
31 Mar 13	35,177	4,162	8,960	4,905

Quality Earnings: SAN1 N has high quality earnings.

Growing Profit Margin: SAN1 N's current net profit margins (19.8%) are higher than last year (14.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SAN1 N's earnings have grown by 13.1% per year over the past 5 years.

Accelerating Growth: SAN1 N's earnings growth over the past year (41.5%) exceeds its 5-year average (13.1% per year).

Earnings vs Industry: SAN1 N earnings growth over the past year (41.5%) exceeded the Pharmaceuticals industry 7.9%.

Sanofi Past Earnings Performance

Past criteria checks 5/6

Key information

Recent past performance updates

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Recent updates

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Sanofi Reportedly in Talks with French Government over Opella Sale

Clayton, Dubilier & Rice Reportedly Nears €15 Billion Deal for Sanofi Consumer Health Unit

Sanofi Healthcare Bidders Reportedly Revising Offers over Talc Concerns

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Sanofi Announces Board and Committee Appointments

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies